BioSpectrum Asia

Thermo Fisher enables scalable gene therapy workflows

-

Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System, a complete, optimised solution that simplifies the AAV vector production workflow. The all-in-one AAV-MAX system increases productivi­ty and cost efficiency by delivering high viral titers using Viral Production Cells 2.0, a new, clonally documented, 293F-derived mammalian cell line. AAV is crucial to the field of gene therapy; more than 1,300 unique gene therapy products are currently under developmen­t, and nearly half are reliant on AAV. The ability to scale production is critical to bringing down costs and accelerati­ng the process from research to commercial­isation. The AAVMAX system has been developed to scale from shake flasks to bioreactor­s. Coupled with the active developmen­t of regulatory­compliant reagents, the system is designed to streamline the transition from research to commercial manufactur­ing. On average, the system can save viral vector researcher­s and developers 25 per cent on plasmid DNA usage and 50 per cent on production costs compared to polyethyle­neimine (PEI)based mammalian production systems.

 ?? ??

Newspapers in English

Newspapers from India